Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Effects of selenium supplementation on cardiovascular disease incidence and mortality: secondary analyses in a randomized clinical trial.

Stranges S, Marshall JR, Trevisan M, Natarajan R, Donahue RP, Combs GF, Farinaro E, Clark LC, Reid ME.

Am J Epidemiol. 2006 Apr 15;163(8):694-9.

2.

Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial.

Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF Jr, Slate EH, Fischbach LA, Marshall JR, Clark LC.

Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):630-9.

3.

Selenium supplementation and lung cancer incidence: an update of the nutritional prevention of cancer trial.

Reid ME, Duffield-Lillico AJ, Garland L, Turnbull BW, Clark LC, Marshall JR.

Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1285-91.

4.

Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial.

Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF, Cappuccio FP, Ceriello A, Reid ME.

Ann Intern Med. 2007 Aug 21;147(4):217-23.

PMID:
17620655
5.

Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial.

Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs GF Jr, Park HK, Gross EG, Graham GF, Stratton MS, Marshall JR, Clark LC; Nutritional Prevention of Cancer Study Group..

J Natl Cancer Inst. 2003 Oct 1;95(19):1477-81.

6.

The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals.

Hercberg S, Galan P, Preziosi P, Bertrais S, Mennen L, Malvy D, Roussel AM, Favier A, Briançon S.

Arch Intern Med. 2004 Nov 22;164(21):2335-42. Erratum in: Arch Intern Med. 2005 Feb 14;165(3):286.

7.

Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial.

Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, Marshall JR, Clark LC; Nutritional Prevention of Cancer Study Group..

BJU Int. 2003 May;91(7):608-12.

8.

Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.

Brunekreef B, Beelen R, Hoek G, Schouten L, Bausch-Goldbohm S, Fischer P, Armstrong B, Hughes E, Jerrett M, van den Brandt P.

Res Rep Health Eff Inst. 2009 Mar;(139):5-71; discussion 73-89.

PMID:
19554969
9.

Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.

Steinhubl SR, Bhatt DL, Brennan DM, Montalescot G, Hankey GJ, Eikelboom JW, Berger PB, Topol EJ; CHARISMA Investigators..

Ann Intern Med. 2009 Mar 17;150(6):379-86.

PMID:
19293071
10.

Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States).

Cook NR, Le IM, Manson JE, Buring JE, Hennekens CH.

Cancer Causes Control. 2000 Aug;11(7):617-26.

PMID:
10977106
11.

Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial.

Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S, Rounder J.

Br J Urol. 1998 May;81(5):730-4.

PMID:
9634050
12.
13.

Effects of long-term antioxidant supplementation and association of serum antioxidant concentrations with risk of metabolic syndrome in adults.

Czernichow S, Vergnaud AC, Galan P, Arnaud J, Favier A, Faure H, Huxley R, Hercberg S, Ahluwalia N.

Am J Clin Nutr. 2009 Aug;90(2):329-35. doi: 10.3945/ajcn.2009.27635.

15.

Antioxidant supplementation increases the risk of skin cancers in women but not in men.

Hercberg S, Ezzedine K, Guinot C, Preziosi P, Galan P, Bertrais S, Estaquio C, Briançon S, Favier A, Latreille J, Malvy D.

J Nutr. 2007 Sep;137(9):2098-105.

16.

Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial.

Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK, Lavori PW.

J Natl Cancer Inst. 2008 Jul 16;100(14):996-1002. doi: 10.1093/jnci/djn209.

17.

Long-term risk of cardiovascular disease in 10-year survivors of breast cancer.

Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, Taylor CW, van Leeuwen FE.

J Natl Cancer Inst. 2007 Mar 7;99(5):365-75.

18.
20.

Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).

Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, Edelman JM, Dahlöf B, Devereux RB; LIFE Study Investigators..

Circulation. 2009 Apr 14;119(14):1883-91. doi: 10.1161/CIRCULATIONAHA.108.812313.

Items per page

Supplemental Content

Support Center